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Abstract
Background and objectives Periprosthetic aortic regurgi-
tation (PPR) after transcatheter aortic valve implantation
(TAVI) remains an important issue associated with impaired
long-term outcomes. The current randomised study aims to
evaluate potential differences between the balloon-expand-
able Edwards SAPIEN-3 and the self-expanding Medtronic
CoreValve system with the main focus on post-TAVI PPR
by means of novel imaging endpoints, and an additional
focus on other clinical endpoints.
Endpoints The primary endpoint of this study is quantita-
tive assessment of the severity of post-procedural PPR using
cardiac magnetic resonance imaging. Several other novel
imaging modalities (X-ray contrast angiography, echocar-
diography) are used as secondary imaging modalities for
the assessment of PPR following TAVI. Secondary objec-
tives of the study include clinical outcomes such as cerebral
and kidney injury related to TAVI, and quality of life.
Methods and design The ELECT study is a single-centre,
prospective, two-armed randomised controlled trial. For
the purpose of this study, 108 consecutive adult patients
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suitable for transfemoral TAVI will be randomly allocated
to receive the SAPIEN-3 (n = 54) or the CoreValve system
(n = 54).
Discussion The ELECT trial is the first randomised con-
trolled trial to quantitatively compare the extent of post-
TAVI PPR between the SAPIEN-3 and CoreValve. Fur-
thermore, it will evaluate potential differences between the
two prostheses with regard to mid-term clinical outcome
and quality of life.
Keywords Transcatheter aortic valve implantation ·
Periprosthetic aortic regurgitation · SAPIEN-3 · CoreValve
Background
Transcatheter aortic valve implantation (TAVI) is a valid
treatment strategy for patients with severe symptomatic
aortic stenosis who are regarded as being at high risk [1,
2] or as unable to undergo open-heart surgery [3]. Two
transcatheter heart valves (THVs) based on different tech-
nical concepts have been developed and are widely used.
These are the balloon-expandable SAPIEN THV (Edwards
Lifesciences, Irvine, CA, USA), and the self-expanding
CoreValve THV (CV-THV) (Medtronic, Minneapolis, MN,
USA). Both THVs have shown excellent clinical results, but
each has specific features, advantages and disadvantages [2,
4, 5].
Currently available evidence suggests that TAVI is fea-
sible and provides long-term haemodynamic and clinical
improvements, but questions remain concerning the safety
and durability of this technique. Several important compli-
cations of TAVI have to be addressed in order to warrant
the wider use of this procedure [6, 7]. Significant concerns
have been raised about the high incidence of post-procedu-
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ral periprosthetic aortic regurgitation (PPR) [1, 2] which is
associated with increased mortality [8–11]. Other impor-
tant procedural-related complications are cerebrovascular
events [12], cardiac conduction disorders [13] and acute
kidney injury [14, 15].
It has been estimated that between 41–100% of patients
have some degree of PPR following TAVI (mild >45%;
moderately severe 2–12%) [10, 16]. Even mild PPR is
associated with 10–15% higher mortality after two years in
comparison with patients with either no or only a trace of
PPR, as shown in the PARTNER cohort A [4]. The extent
and severity of native valve and left ventricular outflow tract
(LVOT) calcification, undersizing of the valve prosthesis
relative to the dimensions of the aortic annulus, suboptimal
placement of the prosthesis and incomplete apposition of
the stent frame owing to calcification in the device landing
zone are all known mechanisms of PPR following TAVI
[17]. However, the impact of prosthesis type (S3-THV or
CV-THV) on the risk of post-TAVI PPR is less clear.
A few recent reports [17, 18], one of which was the
only randomised trial to compare SAPIEN XT-THV (SXT-
THV) (Edwards Lifesciences, Irvine, CA, USA) with CV-
THV (CHOICE study), have suggested differences in the
haemodynamic performance of both THVs where the use of
CV-THV was associated with a higher rate of residual PPR.
However, the operator’s familiarity with the device and sub-
jective measurement of PPR using unidimensional X-ray
angiography images or two-dimensional (2D) echocardiog-
raphy may bias the results. Hence, an adequately powered
randomised study using quantitative assessment techniques
may clarify the difference in severity of PPR between SXT-
THV and CV-THV more reliably.
Although 2D echocardiography is currently considered
the reference standard for evaluation and grading of aortic
regurgitation, PPR is difficult to detect and quantify using
conventional 2D echocardiography. In PPR, eccentric jets
may become entrained along the left ventricular wall, which
tends to alter their appearance and hence the perception of
PPR severity [19]. Moreover, the possible presence of mul-
tiple jets originating from different periprosthetic locations
makes their cumulative impact on the overall importance of
PPR difficult to judge. Furthermore, in obese patients and
patients with chronic obstructive pulmonary disease, the
acoustic window at transthoracic echocardiography may be
inadequate for comprehensive examination of the valves.
Finally, this evaluation is also subject to inter- and in-
tra-observer variability. For these reasons, other diagnos-
tic modalities such as three-dimensional transoesophageal
echocardiography (3D-TEE) [20, 21], phase contrast mag-
netic resonance imaging (MRI) [22], and X-ray contrast
aortography [23] have been proposed for quantification of
PPR after TAVI. These modalities can be used to measure
the severity of aortic regurgitation by quantifying regurgi-
tant volume and regurgitant fraction, thus minimising ob-
server dependency.
Recently, the SAPIEN-3 THV (S3-THV) (Edwards Life-
sciences, Irvine, CA, USA) was introduced [24] which,
besides a differently designed stent frame, has an addi-
tional outer skirt in order to minimise post-TAVI PPR [5,
25]. However, whether this new feature will be effective
in preventing post-TAVI PPR in daily practice remains to
be established as well as the direct comparison versus the
CV-THV. We designed a clinical trial for the randomised
comparison of S3-THV and CV-THV in a routine TAVI
population focusing primarily on post-TAVI PPR measured
by different innovative imaging modalities, which allow
a more accurate and observer-independent quantification of
the PPR.
Methods and design
The ELECT study is a single-centre, prospective, two-
armed randomised controlled trial. Consecutive adult males
or females, judged eligible for transfemoral TAVI by the
local multidisciplinary heart team, and meeting the inclu-
sion criteria will be approached for inclusion in this study.
Device size selection will be based on charts provided by
the manufacturer and on the pre-procedural multislice com-
puted tomography (MSCT) annular perimeter. The ELECT
trial has been designed in accordance with the ethical prin-
ciples of the Declaration of Helsinki. The Ethics Committee
of the University Medical Center Utrecht has given its full
approval for the study and patients who agree to participate
will be asked for written informed consent.
Inclusion criteria
In order to be eligible to participate in this study, sub-
jects must meet all of the following criteria: The patient
must be ≥18 years of age and diagnosed with severe symp-
tomatic aortic stenosis, judged inoperable or at high surgical
risk (EuroSCORE >15% or other criteria that make surgery
high risk by a consensus among cardiologists and cardiac
surgeons in the heart team) and deemed eligible for trans-
femoral TAVI. The diameter of the aortic annulus diameter
should be ≥18 and 28 mm assessed with MSCT. There
should be no contraindications to study requirements such
as MRI or TEE.
Exclusion criteria
Patients unable or unwilling to give informed consent are
excluded from this study, as are patients whose aortic an-
nulus diameter does not meet the inclusion criteria.
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Fig. 1 Flowchart of the study
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Post-procedural aortic angiogram






Within 5 days post-TAVI
Follow-up 6 months
Randomisation and interventions
Patients who meet all the inclusion criteria and none of
the exclusion criteria will be randomised in consecutive
order. After successful puncture of the femoral artery cho-
sen as entry site for TAVI, subjects will be randomised in
a 1:1 fashion using sealed envelopes, to receive either an
S3-THV or a CV-THV (Fig. 1).
Both prostheses (S3-THV and CV-THV) have received
the CE mark of approval for the treatment of severe aor-
tic stenosis. Determination of prosthesis size is based on
the aortic annulus diameter, using pre-procedural contrast-
enhanced MSCT. The S3-THV is provided in three sizes:
23 mm, 26 mm and 29 mm (for native annulus diameters
18–22 mm, 21–25 mm, and 24–28 mm, respectively). The
self-expanding CV-THV is available in four sizes: 23 mm,
26 mm, 29 mm and 31 mm (for native aortic annulus di-
ameters 18–20 mm, 20–23 mm, 23–27 mm, and 27–28 mm,
respectively). In order to be able to randomise patients to
receive S3-THV or CV-THV, only patients with an annular
diameter range between ≥18 and 28 mm will be included
in this study.
TAVI procedure
All procedures will be performed by a highly experienced
team with extensive knowledge of both devices. Details of
the implantation technique for both S3-THVand CV-THV
have been previously reported [10, 24, 26, 27]. The proce-
dure is routinely performed under conscious sedation with
local anaesthesia. Fluoroscopy and intracardiac echocar-
diography are used for procedural guidance [28]. Balloon
pre-dilatation is performed in all cases in accordance with
our routine. Valve deployment is routinely done under rapid
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Fig. 2 X-ray contrast densito-
metry with the special software
(CAAS A-Valve) after transcath-
eter aortic valve implantation
pacing (S3-THV 180 beats/min) or stabilising pacing (CV-
THV 120 beats/min). Patients are monitored for at least
72 h and discharged on a regimen of lifelong low-dose as-
pirin (80–100 mg per day), or an oral anticoagulant (if there
is a clinical indication for this), and 3 months of clopidogrel
(75 mg per day).
Endpoint assessment
Follow-up assessments for the measurements of the primary
and secondary endpoints will be performed at specified time
points.
Primary endpoint
The primary endpoint of this study is quantitative assess-
ment of the severity of post-procedural PPR using CMR.
At day 4 (+1) after TAVI, patients without contraindications
for MRI will undergo cardiac phase contrast MRI for quan-
titative grading of PPR according to the standard grading
criteria.
Secondary endpoints
The secondary endpoints of this study include assessment
of PPR using other novel imaging modalities including
X-ray contrast angiography, and echocardiography (TTE
and TEE). Furthermore, all clinical endpoints as defined by
VARC-2 [29] and the quality of life questionnaires will be
collected.
Contrast X-ray angiography is performed at the end of
each TAVI procedure in order to measure the degree of post-
implantation PPR by contrast densitometry (CAAS A-valve
quantitative regurgitation analysis; Pie Medical Imaging,
Maastricht, the Netherlands) (Fig. 2). Technical details of
this approach have been reported previously [23].
Echocardiography, including TTE and TEE, is per-
formed within five days following TAVI. The use of the
Doppler technique provides accurate information on the
number and severity of paravalvular jets. In addition, 3D
TEE is used to analyse the complete morphology of the
PPR colour flow stream in the region of its origin. Con-
sequently, views from any level can be obtained, and the
direction and extension of PPR jets can be assessed. New
dedicated analysis software (Personal Space Technologies
BV, the Netherlands) designed for the visualisation and
analysis of 3D volumetric echocardiography data will be
used for the quantitative grading of PPR severity in this
study.
Patients will undergo cerebral MRI including a diffusion-
weighted imaging sequence on day 4 (+1) after TAVI, for
detection of new cerebral ischaemic injury [30]. In order
to detect kidney injury related to TAVI, serum and urine
samples (including 24-hour urine) will be collected. Acute
kidney injury will be assessed within 5 days after TAVI
and compared with baseline. Irreversible kidney injury
(VARC-2) will be assessed at 6-month follow-up. In order
to investigate possible mid-term changes in post-TAVI PPR,
valvular function will be evaluated at 6 months using TTE
and 3D TEE as described above. Finally, validated quality
of life questionnaires (KCC-Q, EuroQol EQ-5D and SF-
36) will be used to measure health-related quality of life at
one year follow-up and compared with baseline (Fig. 3).
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Fig. 3 Planned flow diagram
during ELECT trial
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Lost to follow-up (n= )
Refused participation (n=)
Excluded for other reason (n=)
Included (n= ):
Completed  follow-up (n=)
Excluded (n= ):
Lost to follow-up (n= )
Refused participation (n=)
Excluded for other reason (n=)
Statistical analysis
Descriptive statistics will be used to ascertain any imbal-
ance between the arms at baseline. The extent of missing
data will be reported and baseline factors will be compared
for completers and non-completers to assess the extent of
any bias that may result.
Continuous variables are presented as means ± standard
deviation or medians [interquartile range], as considered
appropriate, and categorical variables as counts and per-
centages. Continuous variables will be compared using the
Student t test or Mann-Whitney test, depending on data dis-
tribution. Categorical variables will be compared using chi-
square or Fisher’s exact test, as considered appropriate. For
the analysis of the difference in PPR between each of the
prostheses, log transformation will be performed on the re-
gurgitation volume data before performing a t test, as these
data are expected to be right-skewed. The follow-up analy-
sis for changes in the endpoints in the time within the arms
will be performed using the paired t test and the repeated
measurements analysis of variance. A two-tailed p-value
of less than 0.05 is regarded as statistically significant. All
analyses will be performed according to the intention-to-
treat principle. Data will be analysed using IBM SPSS
Statistics software version 20 (IBM Corp., Armonk, NY,
USA), and R version 2.12.0 (http://www.r-project.org).
Sample size calculation
A sample size calculation for the primary endpoint post-
TAVI PPR has been performed. A literature search on the
difference in the extent of PPR after TAVI between the S3-
THV and CV-THV prostheses has been done. No studies
were found that included a quantitative PPR comparison be-
tween these two prostheses. We used data from 25 patients
treated with TAVI at our centre for a sample size calculation.
PPR quantification in these patients was performed using
cardiac MRI. Because the distribution of these volume data
was skewed to the right, we performed a log transformation
on the original data to improve approximations to normal-
ity (original volumes presented as ml). The log transformed
values were as follows: an overall mean regurgitant volume
of 0.48, an ‘overall’ median regurgitant volume of 0.48, an
overall standard deviation (SD) of 0.53, and a mean regur-
gitant volume of 0.32 for S3-THV and a mean regurgitant
volume of 0.63 for CV-THV. CMR grades of PPR will be
defined according to regurgitation fraction using similar ref-
erence cut-point values according to the standard grading
criteria. As even mild PPR has been shown to be associated
with long-term mortality, any significant difference in post-
TAVI PPR volume between S3-THV and CV-THV is con-
sidered clinically important. The sample size calculation,
including the above-mentioned log transformed values for
mean regurgitant volumes and standard deviations, yielded
a sample size of 49 patients in each arm to show superiority
or equivalence over S3-THV and CV-THV with a power of
80%. As we took an expected dropout rate of 10% into
account, this yielded a total sample size of 54 patients in
each arm.
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Discussion
The ELECT trial is the first randomised controlled trial
to quantitatively compare the magnitude of post-procedural
PPR between the S3-THV prosthesis and CV-THV. Other
important objectives of this trial include assessment of the
value of angiography, transthoracic and (3D) transoesoph-
ageal echocardiography and cardiac MRI for the measure-
ment of post-TAVI PPR severity.
Regardless of the prosthesis type, post-procedural PPR
is a common complication after TAVI associated with in-
creased mortality [17]. A meta-analysis [25] including
45 studies reported an overall incidence of moderate or se-
vere PPR of 11.7% within 30 days after TAVI. The balloon-
expandable S3-THV [24] and self-expanding CV-THV [31]
are two transcatheter heart valves that are in widespread use
worldwide. Few previous studies comparing the haemody-
namic performance of these two types of prosthesis have
suggested a higher incidence of moderate or severe post-
TAVI PPR accompanying the implantation of CV-THV [1,
25].
An important aspect of CV-THV that might increase
the risk of post-TAVI PPR (and thus explain the aforemen-
tioned data) is the intrinsic radial strength of its nitinol
frame, which may not be sufficient for complete apposition
of the prosthesis to the native annulus. This incomplete ap-
position might create periprosthetic gaps, especially in the
presence of calcification along the aortic wall. Furthermore,
an extreme angulation between the left ventricular outflow
tract and the ascending aorta (also called the horizontal
aorta) may reduce the ability of the CV-THV prosthesis to
seal the paravalvular space [25]. Therefore, oversizing and
balloon post-dilatation are more important in CV-THV im-
plantation than in S3-THV implantation. In addition, owing
to the non-cylindrical shape of the CV-THV system, its ef-
fective area inside the aortic annulus depends on the depth
of the prosthesis in the left ventricular outflow tract. There-
fore, in the CV-THV the sealing of the paravalvular space
by the prosthesis also depends on the depth of its implanta-
tion. However, besides the factors mentioned above, which
make CV-THV susceptible to post-TAVI PPR, we also need
to keep in mind that the self-expanding nitinol frame has
the potential to further expand over time. Therefore, the
apposition of the prosthesis frame to the aortic annulus has
the potential to improve gradually, decreasing the extent of
post-TAVI PPR with passage of time.
Interestingly, the recently published results of the
CoreValve US Pivotal Trial [32] showed that the inci-
dence of any PPR after the implantation of CV-THV
decreases over time: 41.1% at discharge and 31.9% at one
year. The latter was also accompanied by a reduction in
the incidence of more-than-mild aortic regurgitation during
follow-up, at 13.8% at discharge, 10.1% at 6 months, and
6.4% at one year. This suggests that measurement of post-
TAVI PPR in the CV-THV during the few first days after
TAVI will probably overestimate its long-term severity. In
the ELECT study, the severity of PPR is also measured
at 6-month follow-up using transthoracic and 3D trans-
oesophageal echocardiography, which allows for a more
reliable comparison between the two prostheses.
One previously published meta-analysis [25] showed
a higher risk of moderate or severe post-procedural PPR
after CV-THV implantation (16%) as compared with
Edwards SAPIEN implantation (9.1%, p = 0.005). The
CHOICE study [18], which is the only randomised head-
to-head trial to date that has compared the balloon-ex-
pandable SXT-THV with the CV-THV system, reported
a significant difference in the frequency of any degree of
PPR (38% in SXT group versus 65% in the CV group,
p < 0.001) and more-than-mild PPR (4.1% in SXT group
versus 18.3% in the CV group, p < 0.001 by angiography)
favouring the balloon-expandable valve. However, the ex-
tent of the PPR in the CHOICE trial was measured using
aortic root angiography immediately after prosthesis im-
plantation, which is an important limitation of this clinical
trial.
On the other hand, the PRAGMATIC [33] study reported
a very low and comparable incidence of more-than-mild
PPR with both Edwards SAPIEN and CV-THV (1.8% and
2.0%, respectively) in a large multicentre propensity score-
matched study. Recently, another study among a selected
group of patients receiving S3-THV or CV-THV reported
a significantly lower rate of mild or severe PPR, lower need
for permanent pacemaker implantation, and higher rate of
device success for the S3-THV compared with CV-THV.
However, this study was limited by its design and small
sample size [34].
Obviously, there is a discrepancy in the incidence of PPR
across different studies that is most probably related to the
challenges in identification and quantification of post-TAVI
PPR. Also, the VARC-2 document [29] did not propose
new diagnostic criteria for adequate assessment of post-
TAVI PPR. The lack of a standardised and validated method
for evaluation of post-TAVI PPR is a major limitation in
comparing echocardiographic PPR analysis performed in
different studies and meta-analyses. Aortic regurgitation
after TAVI usually consists of multiple eccentric jets that
are non-parallel and irregular in shape [21, 35].
Eccentric jets are frequently entrained along the left ven-
tricular wall with fanning of jets as they regurgitate. There-
fore, the eccentric aspects of post-TAVI PPR make the as-
sessment of its severity challenging. Also acoustic shad-
owing from the calcifications and Doppler attenuation from
the prosthesis can obscure regurgitant jets and thus result
in underestimation of their severity [35].
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On the other hand, assessment of PPR severity using
aortic root angiography relies on subjective assessment of
unidimensional images, and can be affected by inter-ob-
server and intra-observer variability.
In the ELECT trial, the severity of PPR is measured
quantitatively using several different modalities, from ded-
icated software for angiography [23] directly post-TAVI
implantation to either transthoracic and transoesophageal
echocardiography (with 3D reconstruction) [20, 21] to car-
diac MRI including phase contrast sequences [22]. The
main focus of the ELECT trial will be the comparison of
the different imaging modalities in assessing PPR, using
CMR as a primary endpoint. This comparison is an impor-
tant aspect of the present trial as to date there is no validated
tool for reliable measurement of post-TAVI PPR.
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